Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07295717
PHASE1

A Study to Evaluate ALN-4285 in Adult Healthy Volunteers

Sponsor: Alnylam Pharmaceuticals

View on ClinicalTrials.gov

Summary

The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285

Official title: A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

76

Start Date

2025-12-12

Completion Date

2027-03-23

Last Updated

2026-03-31

Healthy Volunteers

Yes

Interventions

DRUG

ALN-4285

ALN-4285 will be administered SC

DRUG

Placebo

Placebo will be administered SC

Locations (1)

Clinical Trial Site

London, United Kingdom